Press Release **Lille, 23rd November 2021**

4Living Biotech and Sanofi enter into a collaboration agreement to demonstrate potential clinical efficacy of Mozobil® as a treatment for acute and chronic complications of COVID-19

- 4Living Biotech and Sanofi enter into a clinical collaboration agreement to demonstrate the potential efficacy of Mozobil® in the treatment of severe COVID-19 patients.
- An international Phase 2 clinical trial including 150 patients is planned for the first quarter of 2022.
- 4Living Biotech is the sponsor of the clinical trial.
- Sanofi will supply the product and its placebo for this clinical trial.

Lille, France, November 23rd, 2021 - 4Living Biotech (4LB), a biotechnology company and subsidiary of 4P-Pharma, specializing in the treatment of respiratory infections, announced today that it has entered into a clinical collaboration agreement with Sanofi. The two companies are working together to demonstrate the potential efficacy of Mozobil® for the treatment of acute and long-lasting complications of COVID-19 in a Phase 2 global clinical trial.

This trial leverages on recent studies that have shown that the expression of the CXCR4 receptor by neutrophils and lymphocytes correlates with the severity and morbidity of COVID-19 patients. 4LB and its partners have demonstrated the efficacy of Mozobil® in blocking this receptor to improve the pulmonary pathophysiology associated with respiratory viral infection.

« Acting on the pathophysiology of pulmonary complications related to SARS-CoV-2 infection by decreasing the recruitment of immature neutrophils appeared to us as a particularly relevant approach to treat respiratory viral infections," said Revital Rattenbach, President of 4LB and 4P-Pharma.

4LB has developed a co-proprietary approach of repurposing CXCR4 antagonists, that has been the subject of preclinical and translational studies carried out internally and in collaboration with the laboratory of Prof. François Trottein at the Pasteur Institute in Lille, and the laboratory of Prof. Patrick Berger at the University Hospital in Bordeaux (France).

Press Release **Lille, 23rd November 2021**

Under this agreement with Sanofi, 4LB is responsible for the operational conduct of this Phase 2 clinical trial, with Sanofi providing Mozobil® and placebo.

« We are very pleased to enter into this agreement with Sanofi as a partner of choice to evaluate a potential new therapeutic solution for COVID-19 patients with severe pulmonary complications. This agreement is an excellent example of 4P-Pharma's strategy to work with a strategic partner to accelerate patient access to its innovative programs," concluded Revital Rattenbach.

"Through its collaboration with 4P-Pharma, Sanofi is delighted to continue to advance the fight against COVID-19 and reinforce its partnership approach to promote the research and biotech sector in France," emphasizes Pascal Rigaudy, Global Head, Transplant Brands at Sanofi. *"In parallel to the development of a candidate vaccine, Sanofi contributes to the study of its established treatments that could show potential therapeutic value in COVID-19 through innovative approaches. Should its efficacy be proven, Mozobil®, currently indicated in the stem cell mobilization before autologous transplantation in patients with lymphoma or multiple myeloma, could benefit a new patient population."*

About 4Living Biotech
4Living Biotech is a biotech start-up company dedicated to the development of 4P021, a drug candidate for the treatment of acute respiratory distress due to viral respiratory infection, that targets the recruitment and accumulation of immune cells into the lungs. Thereby 4P021 prevent acute and chronic pulmonary complications associated with viral respiratory infection as COVID-19 or influenza. 4Living Biotech was established in August 2020 and is a majority-owned subsidiary of 4P-Pharma. The company is headquartered at the Institut Pasteur de Lille (France).
https://4p-pharma.com/our-pipeline/pipeline-covid-19/

About 4P-Pharma
4P-Pharma is a French clinical-stage biotechnology company, located at the Institut Pasteur de Lille, specializing in the sourcing and acceleration of early-stage therapeutic molecules addressing unmet medical needs. 4P-Pharma aims to detect the most promising innovations from partners (i.e. academic institutions, biotech companies and TTOs) and performs in-house technological due-diligence applying stringent industry criteria. 4P-Pharma gathers all the relevant actors from the clinic, drug development, finance and business fields to move technologies through developmental decision to bring innovations to clinical phases. Since the foundation of 4P-Pharma, in 2014, more than 300 molecules have been pre-evaluated, a technological due diligence has been carried out on more than 20 of them. Two are now incorporated in clinical-stage asset centric companies owned by 4P-Pharma.
Website: www.4p-pharma.com
LinkedIn: www.linkedin.com/company/4p-pharma
Twitter: @4P_Pharma